Awards & Recognition

PHAR and Co-authors Commended for Work to Improve the Care of Patients with IPF

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown cause, with median survival of 3 to 5 years. Establishing a diagnosis of IPF can be challenging, with misdiagnoses and delays commonly reported, which cause delays in treatment that can slow the disease progression. The researchers at PHAR recently published a study in… read more

PHAR Study Wins Best Poster Award at ISPOR Asia Pacific 2018

Research focusing on schizophrenia, major depressive disorder, and bipolar I disorder conducted by PHAR and supported by Otsuka Pharmaceuticals Development & Commercialization, Inc. and H. Lundbeck A/S was well-represented at ISPOR Asia Pacific 2018. One study focusing on the effect of timing of long-acting injectable initiation in patients with schizophrenia was selected as an oral… read more

PHAR Makes 15 Research Presentations at Conferences Across the US in May

PHAR had 14 posters and 1 oral presentation at a series of recent conferences, including the ISPOR 22nd Annual International Meeting, National Lipid Association Scientific Sessions, American Thoracic Society International Conference, and the Annual Meeting of the American Psychiatric Association. Four posters at ISPOR were honored with the Research Poster Finalist Award. The study topics… read more

PHAR Poster on Cystic Fibrosis Awarded Bronze Medal at AMCP 2016

This retrospective study used insurance claims data to examine the extent of twice-daily use of dornase alfa among cystic fibrosis patients. The study was done in partnership with researchers at Genentech, Inc. and presented at Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting in San Francisco. See the full poster here.

Cushing’s Disease Research Selected for Oral Presentation at ENDO 2016

A study conducted by the researchers at PHAR was selected for oral presentation at Endocrine Society’s 2016 Annual Meeting in Boston in April. The study used data from medical records at 8 US endocrine centers to describe treatment outcomes for Cushing’s Disease patients . The findings of the study can be viewed here. Including this… read more

Abstract Highlighted in ASH Daily Report

An abstract submitted by researchers at PHAR and Jazz Pharmaceuticals was highlighted by the American Society of Hematology (ASH) at their 57th Annual Meeting. The study estimated the total 100-day and one-year costs associated with inpatient hematopoietic stem cell transplantation, stratified by type of conditioning regimen and other potential contributors to cost. Researchers found that… read more

PHAR Study Takes AMCP Silver Medal 2 Years in a Row

For the second year in a row, PHAR was presented with a Silver Medal by the Academy of Managed Care Pharmacy. This year, the award was for a study on health care resource use and costs associated with high OCS use in patients with asthma, conducted by researchers at PHAR and Genentech, Inc., The retrospective… read more

Study by PHAR Researchers Wins Silver Medal at AMCP Nexus Conference

The Academy of Managed Care Pharmacy awarded its Silver Medal to a study conducted by PHAR and researchers from Novartis Pharmaceuticals Corporation. This retrospective claims analysis found that the per patient healthcare cost of Cushing’s disease care was more than double the cost for diabetes care and quadruple the cost for population-based controls. The study… read more

PHAR Study on Asthma-Related Outcomes Receives Silver Medal at AMCP Annual Meeting

PHAR partnered with researchers at Genentech Inc. to study the relationship between the Healthcare Effectiveness Data and Information Set (HEDIS) and Asthma-Related Outcomes. Patients with low asthma medication ratio (AMR< 0.5) had worse asthma control by multiple measures including hospitalization/ED visits, OCS use, and SABA use. The number of asthma-related office visits was also slightly… read more

Journal Watch Reports on PHAR Study

According to Andrew M. Kaunitz, MD, Editor in chief of Journal Watch, Women’s Health, a study by PHAR researchers demonstrates that “except in women with mutations that raise risk for ovarian cancer, bilateral oophorectomy should not be performed at hysterectomy for benign indications.” Dr. Kaunitz is  is Professor and Associate Chair of the Department of Obstetrics and… read more